Predictors of myelodysplastic syndrome in Minnesota

明尼苏达州骨髓增生异常综合征的预测因子

基本信息

批准号：
8036091
负责人：
Julie Ann Ross
金额：
$ 55.53万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-04-01 至 2015-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8036091
关键词：
Accounting Acute Myelocytic Leukemia Address Adult Adult Acute Myeloblastic Leukemia Affect Age American American Indians Anti-Inflammatory Agents Anti-inflammatory Asians Benzene British Cancer Center Case-Control Studies Categories Cells Cessation of life Chemical Exposure Chemicals Chronic Myelomonocytic Leukemia Classification Clinic Collection Controlled Study DNA Data Development Diagnosis Diet Drug usage Dysmyelopoietic Syndromes Enrollment Epidemiologic Studies Epidemiology Etiology Exposure to Family history of Frequencies Funding Future Genetic Predisposition to Disease Genotype Goals Health Hematologic Neoplasms Hematopoietic Neoplasms Hematopoietic System Hispanics Hospitals Incidence Individual International Knowledge Lead Letters Literature Malignant Glioma Malignant Neoplasms Medical Records Minnesota Myeloid Leukemia Newly Diagnosed Not Hispanic or Latino Obesity Occupational Exposure Outcome Overweight Pacific Island Americans Pathology Patients Personal Communication Pesticides Population Control Positioning Attribute Prevention Prevention strategy Process Prognostic Factor Public Health Questionnaires Radiation Recording of previous events Refractory anemias Reporting Research Infrastructure Residual state Rheumatoid Arthritis Risk Risk Factors Role SEER Program Saliva Solvents Suggestion Surveys Susceptibility Gene System Time United States United States National Institutes of Health World Health Organization adult leukemia base case control chemotherapy cigarette smoking comparative genomic hybridization cost effective follow-up genetic analysis high risk improved indexing insight leukemia lifestyle factors neoplasm registry novel pesticide exposure population based prognostic public health relevance

项目摘要

DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is a heterogeneous disruption of the hematopoietic system that can lead to the development of acute myeloid leukemia (AML) in about 1/3 of cases. MDS became reportable to the Surveillance, Epidemiology and End Results program in 2001. It is estimated that about 10,000 MDS cases are newly diagnosed each year in the United States, which is similar to the number of malignant gliomas. Minnesota has one of the higher incidence rates of MDS. With the exception of chemotherapy and radiation treatment for other cancers, which is associated with < 5% of MDS, little is known about causes. Of the few studies conducted (mostly <200 cases and/or clinic-based), there is a suggestion of a role for occupational exposures, cigarette smoking, and some other lifestyle factors, many of which are similar to those associated with AML. We are proposing a new population-based study of MDS in Minnesota that utilizes the questionnaire and infrastructure of our ongoing adult myeloid leukemia study that concludes in early 2010. A total of 705 MDS cases and 705 frequency-matched population controls will be enrolled over a 4 1/2 year period (April 1, 2010 - October 31, 2014). In addition to evaluating potential risk factors such as those described above, we will explore risk factors by central pathology reviewed subtypes of MDS by integrating data from our adult myeloid leukemia study. We will also determine those environmental or other exogenous risk factors that are common to AML and MDS versus those risk factors that are distinct. Additionally, we will explore whether there are risk factors more common to MDS cases that are at risk of progressing to AML, which includes the novel incorporation of prognostic scoring systems. Finally, we will collect saliva from MDS cases and controls for future genetic susceptibility studies. This study will be the largest population-based study of MDS conducted to date. With the incorporation of a successful infrastructure, and the ability to make comparisons with a similar existing study of myeloid leukemia, we are uniquely positioned to answer important etiological questions regarding MDS. The significance of this proposal also relates to potential prevention strategies for adult AML, which has important public health implications. Public Health Relevance: Myelodysplastic syndrome (MDS) is a blood cancer that affects about 10,000 people in the United States each year. Little is known about why MDS happens or why some people with MDS eventually develop leukemia. We are proposing one of the largest epidemiological studies of MDS ever conducted, with the goal of being able to identify risk factors that could lead to prevention.

描述（由申请人提供）：骨髓增生综合征（MDS）是造血系统的异质破坏，可导致大约1/3病例的急性髓样白血病（AML）的发展。 MDS在2001年的监视，流行病学和最终结果计划可报告。据估计，在美国，每年新诊断出约10,000例MDS病例，这与恶性神经胶质瘤的数量相似。明尼苏达州的发病率是MDS的较高。除了对其他癌症的化学疗法和放射治疗（与MD的5％相关的化学疗法和放射治疗），对原因知之甚少。在少数进行的研究（主要是200例和/或基于诊所）的研究中，有一个建议，暗示了职业暴露，吸烟和其他一些生活方式因素，其中许多与与AML相关的生活方式相似。我们提出了一项针对明尼苏达州MDS的新的基于人群的研究，该研究利用了我们正在进行的成年成人髓样白血病研究的问卷和基础设施，该研究在2010年初结束。总共705例MDS病例和705个频率匹配的人口控制将在4 1/2年期间（2010年4月1日至2010年10月1日至2014年10月31日，2014年4月1日）。除了评估上述潜在危险因素（例如上述）外，我们还将通过中央病理学探索危险因素，通过整合我们成人髓样白血病研究的数据来审查MDS的亚型。我们还将确定AML和MDS共有的环境或其他外源危险因素与那些与众不同的危险因素。此外，我们将探讨是否存在有可能进展为AML风险的MDS病例的风险因素，其中包括预后评分系统的新颖纳入。最后，我们将从MDS病例和对照组中收集唾液，以进行未来的遗传易感性研究。这项研究将是迄今为止对MDS进行的最大基于人群的研究。通过合并成功的基础设施，以及与现有的髓样白血病进行比较的能力，我们有独特的位置可以回答有关MD的重要病因学问题。该提案的重要性还涉及对成人AML的潜在预防策略，这具有重要的公共卫生影响。公共卫生相关性：骨髓增生综合征（MDS）是一种血液癌，每年影响约10,000人。关于MD为什么会发生的原因，或者为什么有些人最终患有白血病的原因，知之甚少。我们提出了有史以来最大的MDS流行病学研究之一，目的是能够识别可能导致预防的危险因素。